Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition-Reference-Cited by-同舟云学术

Correction: MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition

Published:2019-10-16 Issue:10 Volume:17 Page:e3000529
ISSN:1545-7885
Container-title:PLOS Biology
language:en
Short-container-title:PLoS Biol

Author:

Walle Lieselotte Vande,Stowe Irma B.,Šácha Pavel,Lee Bettina L.,Demon Dieter,Fossoul Amelie,Van Hauwermeiren Filip,Saavedra Pedro H. V.,Šimon Petr,Šubr Vladimír,Kostka Libor,Stivala Craig E.,Pham Victoria C.,Staben Steven T.,Yamazoe Sayumi,Konvalinka Jan,Kayagaki Nobuhiko,Lamkanfi Mohamed

Publisher

Public Library of Science (PLoS)

Subject

General Agricultural and Biological Sciences,General Immunology and Microbiology,General Biochemistry, Genetics and Molecular Biology,General Neuroscience

Reference1 articles.

1. MCC950/CRID3 potently targets the NACHT domain of wild-type NLRP3 but not disease-associated mutants for inflammasome inhibition;L Vande Walle;PLoS Biol,2019

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical characteristics of Chinese neonates with neonatal-onset multisystem inflammatory disease: a case report and literature review;Frontiers in Immunology;2024-01-05

2. The NLRP3 inflammasome in age-related eye disease: Evidence-based connexin hemichannel therapeutics;Experimental Eye Research;2022-02

3. Identification of NLRP3PYD Homo-Oligomerization Inhibitors with Anti-Inflammatory Activity;International Journal of Molecular Sciences;2022-01-31

4. NLRP3 Inflammasome in Vascular Disease: A Recurrent Villain to Combat Pharmacologically;Antioxidants;2022-01-29

5. Diagnosis and Management of the Cryopyrin-Associated Periodic Syndromes (CAPS): What Do We Know Today?;Journal of Clinical Medicine;2021-01-01